Diseases
The Society of Nuclear Medicine and Molecular Imaging (SNMMI), American Society of Nuclear Cardiology (ASNC), European Association of Nuclear Medicine (EANM), and American College of Nuclear Medicine (ACNM) have issued a new clinical guideline for 18F-flurpiridaz PET myocardial perfusion imaging (MPI) and blood flow quantitation. The guideline is intended to
Diseases
AstraZeneca's Fasenra, a treatment for chronic obstructive pulmonary disease (COPD), has failed to meet statistical significance in the primary endpoint of the RESOLUTE Phase III trial. Despite this setback, Fasenra remains a leading treatment for severe eosinophilic asthma (SEA) in over 80 countries, including the US, Japan, EU,
Diseases
AstraZeneca's flagship treatment, Fasenra (benralizumab), has shown promise in treating various respiratory diseases, but its latest trial, RESOLUTE, failed to demonstrate statistical significance in treating chronic obstructive pulmonary disease (COPD). The trial showed numerical improvement, but the results were not enough to meet the primary endpoint. Despite this
Diseases
MapLight Therapeutics has initiated a Phase 2 study to evaluate the efficacy, safety, and tolerability of ML-007C-MA, an investigational novel M 1 /M 4 agonist, as a potential treatment for Alzheimer's disease psychosis (ADP). The study, known as VISTA, is a randomized, double-blind, placebo-controlled trial that aims to
Diseases
Research conducted at Guangxi Medical University in Guangxi, People's Republic of China, has led to the identification of a set of genes associated with aging and their potential role in coronary artery disease (CAD). The study aimed to investigate how aging hallmarks exert their roles in CAD and
Diseases
A patent application filed by a team of researchers from the Albert-Ludwigs-Universitaet Freiburg in Germany, led by Harmut Hengel, has disclosed novel antibodies and antigen binding fragments targeting the extracellular domains of human cytomegalovirus (HCMV) glycoproteins gp34 and gp68. The application, filed on June 10, 2022, and made available online
Diseases
Regeneron is quickly moving forward with FDA approval plans for its treatment garetosmab in fibrodysplasia ossificans progressiva (FOP) after a phase 3 clinical trial demonstrated a significant reduction in abnormal bone lesions. The study, which enrolled 63 adults with FOP, randomized patients to receive one of two doses of garetosmab
Diseases
Researchers at Ludwig-Maximilians-University Munich have evaluated the distribution and risk of disease progression in first-line therapy of unresected metastatic colorectal cancer patients. The study analyzed data from 11 clinical trials to provide guidance for the timing of disease reassessments during first-line therapy. Key Takeaways: * The maximum frequency of disease progression
Diseases
A novel drug called baxdrostat has been shown to significantly lower blood pressure in patients with treatment-resistant hypertension, while also potentially aiding kidney health by reducing inflammation and scarring caused by high aldosterone levels. The medication, which targets the production of the hormone aldosterone, has been hailed as a "
Diseases
Researchers at the Federal Research Centre of Nutrition have explored the potential of plant protein-based foods in correcting dietary patterns for alimentary-dependent diseases (ADDs) of the digestive system. A review of 66 papers analyzed the use of plant proteins in treating diseases such as metabolically associated fatty liver disease, gastroesophageal
Diseases
A comprehensive pipeline report provides insights into the rapidly evolving landscape of Chronic Obstructive Pulmonary Disease (COPD) treatment, with over 65 companies and 70+ emerging therapies in various stages of development. The report highlights promising pipeline drugs, clinical trials, and market opportunities, offering a valuable resource for stakeholders in the
Diseases
Recent research by a team of scientists at Johns Hopkins University has shed new light on the relationship between cancer and autoimmune diseases. By analyzing fragmentation patterns in plasma cell-free DNA (cfDNA), researchers found that individuals with venous thromboembolism, systemic lupus erythematosus, dermatomyositis, or scleroderma have cfDNA fragmentation signatures that
